A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Inflammatory mediators (TNF-α, IL-1, IL-6, histamine, bradykinin) and chemokines direct leukocyte recruitment and activation. Dysregulation of these signaling pathways—excessive production, impaired clearance, or aberrant receptor signaling—drives chronic inflammation and tissue damage in pathologic states.
Study specific mediators in context of disease models: TNF in sepsis, IL-6 in rheumatoid arthritis, chemokine gradients in leukocyte infiltration.
Not all cytokines are pro-inflammatory; many are essential for resolution (IL-10, TGF-β). Chemokine gradients form a directed 'trail' not a general attractant field.
From your study of acute inflammation, you know that the inflammatory response begins with tissue injury or pathogen detection, produces redness, swelling, heat, and pain, and is meant to be self-limiting. The inflammatory mediators you're now examining are the molecular implementation of that process — the specific proteins that carry messages between cells to coordinate recruitment, activation, and ultimately resolution. Understanding pathophysiology here means understanding not just the normal message but what happens when the signaling system is dysregulated.
TNF-α (tumor necrosis factor-alpha) is the prototypical early-alarm cytokine. Macrophages secrete it within minutes of detecting pathogens via pattern recognition receptors like TLRs. TNF-α binds receptors on endothelial cells, inducing expression of adhesion molecules (E-selectin, ICAM-1) that allow circulating neutrophils to roll, arrest, and transmigrate into tissue. TNF-α also acts systemically: at moderate concentrations it induces fever and acute-phase protein production; at high concentrations it causes endothelial injury, vasodilation, and hypotension. In sepsis, uncontrolled TNF-α release contributes directly to cardiovascular collapse — an adaptive defense signal that has become destructive at massive scale. Anti-TNF biologics (infliximab, etanercept) exploit this by blocking TNF-α to treat rheumatoid arthritis, but they simultaneously increase susceptibility to tuberculosis, illustrating the tradeoff of dampening a central alarm signal.
Chemokines operate at the next level of specificity — they don't just tell leukocytes to "go to the site," they create a spatial gradient in the tissue that gives leukocytes directional information. CXCL8 (IL-8) establishes a gradient from the injury site outward, and neutrophils bearing CXCR2 receptors follow the rising chemokine concentration toward the source. Think of it as a molecular scent trail rather than a nonspecific attractant cloud. Different chemokine-receptor pairs recruit different leukocyte subsets: CXCL10 recruits T cells via CXCR3; CCL2 (MCP-1) recruits monocytes via CCR2. This selectivity explains why neutrophils dominate acute bacterial infections while T cells and macrophages dominate chronic viral infections — the chemokine milieu is different.
The critical insight in pathophysiology is that inflammatory signaling is bidirectional: resolution requires active suppression, not merely the absence of stimulation. IL-10 and TGF-β are anti-inflammatory cytokines secreted by regulatory T cells and macrophages that suppress TNF-α and IL-6 production and promote tissue repair. When this resolution program fails — due to persistent antigen, genetic predisposition, or aberrant immune activation — inflammation becomes chronic. Rheumatoid arthritis exemplifies this: synovial macrophages chronically produce TNF-α and IL-6 even without ongoing infection, driven by immune complexes and synovial microenvironment factors. The cartilage destruction follows from chronic neutrophil and macrophage activation, not from a failure of the initial inflammatory signal to fire, but from a failure of that signal to ever turn off.